Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CUL4A | Q13619 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.47 |
| ▸ | ALDH3A1 | P30838 | 6/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349059 | 0.78 | ACHE (0.60) | CUL4ACES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL31238759 | 0.78 | CUL4A (0.58) | CUL4ACES1RXFP1ACHEALDH1A1 | |
| SCHEMBL15571751 | 0.75 | CUL4A (1.00) | CUL4ACES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL21001776 | 0.73 | ACHE (0.57) | CUL4ACES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL4624674 | 0.72 | CUL4A (0.68) | CUL4ACES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL12674685 | 0.70 | ALDH1A1 (0.76) | CUL4ACES1RXFP1ACHEALDH1A1 | |
| SCHEMBL22667286 | 0.69 | CUL4A (0.68) | CUL4ACES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL30403461 | 0.69 | CUL4A (0.68) | CUL4ACES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL29220077 | 0.68 | ALDH1A1 (0.67) | CUL4ACES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL13196466 | 0.67 | CUL4A (0.43) | CUL4ACES1ACHEALDH1A1ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090220554-A1 | Transglutaminase Inhibitors and Methods of Use Thereof | PHARMIX CORPORATION | 2009-09-03 | — | — | US | disclosed |
| US-20090220554-A1 | Transglutaminase Inhibitors and Methods of Use Thereof | PHARMIX CORPORATION | 2009-09-03 | — | — | US | disclosed |
| US-20090220554-A1 | Transglutaminase Inhibitors and Methods of Use Thereof | PHARMIX CORPORATION | 2009-09-03 | — | — | US | disclosed |
| EP-1954285-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | Alvine Pharmaceuticals, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007050795-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | ALVINE PHARMACEUTICALS, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220554-A1 | Transglutaminase Inhibitors and Methods of Use Thereof | TGM2, TGM3, TGM1 | CUL4A 4072/4885CES1 364/4885RXFP1 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.